Business Wire

UT-ICON-HEALTH-&-FITNESS

Share
iFit® Introduces Fitness Breakthrough: Personalized and Automatic Heart Rate Training with iFit ActivePulse™

iFit, a global leader in interactive connected fitness technology, today announced the upcoming release of iFit ActivePulse automatic heart rate training. iFit’s cutting edge technology uses complex algorithms so an iFit subscriber’s heart rate controls the treadmill in real time, automatically adjusting the speed and incline to maintain the optimal heart rate zone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005174/en/

iFit’s game-changing innovation removes the guesswork from heart rate training, by allowing a member’s heart rate to automatically scale and tailor iFit’s vast library of workouts to their individual fitness levels and goals. iFit has applied for patent protection on ActivePulse, which will be available on all iFit-controlled NordicTrack® , ProForm® and Freemotion® treadmills.

Until now, the benefits of heart rate training have hinged on how well a person is able to manually monitor and adjust their effort in order to remain in a particular heart rate zone. In contrast, iFit ActivePulse creates a real-time feedback loop between a user’s measured heart rate and the treadmill’s speed and incline.

iFit ActivePulse heart rate training keeps the user in their optimal zone, while enabling them to accomplish their fitness goals by targeting different heart rate zones.

“ActivePulse lets each iFit customer's heart rate personalize their treadmill workout without the complicated calculations and constant manual adjustments that have long been associated with heart rate training,” said Mark Watterson, President of iFit. “ActivePulse provides a workout that is catered not just to a member; it is catered to that member based on how their heart rate is functioning during the workout.”

Daily variables such as hydration, sleep, and stress have a direct impact on heart rate, therefore the effectiveness of a given workout can vary from one day to the next based on heart rate performance. iFit ActivePulse scales and tailors the intensity of any iFit program to optimize the workout based on their heart rate at that moment—even incorporating advanced algorithms to gradually “learn” their unique behavioral patterns over time.

Heart rate training—the concept of exercising within predetermined ranges (or “zones”) of a user’s maximum heart rate to achieve specific fitness goals—has been used by elite athletes and coaches around the world for more than 30 years. With various heart rate zones corresponding to fitness goals like building endurance, and promoting recovery, heart rate training is widely accepted as the most intelligent way to achieve consistent and measurable progress towards specific fitness goals.

iFit ActivePulse is compatible with leading Bluetooth® heart rate monitors with broadcast functionality, including the iFit SmartBeat™ forearm heart rate monitor, as well as third-party devices from brands including Polar®, Garmin®, Wahoo® and WHOOP®.

Included with all iFit memberships, ActivePulse will be available on all iFit-enabled NordicTrack, ProForm and Freemotion treadmills via an automatic iFit software update in January 2021. The feature will become available for stationary bikes, rowers, and ellipticals from NordicTrack, ProForm and Freemotion soon thereafter.

About iFit

iFit is the patented connected fitness platform that powers NordicTrack, ProForm and Freemotion equipment. ICON, the creator and owner of iFit, pioneered interactive fitness and was issued its first of many patents for its training technology in the early 2000s. Founded with the belief that the majority of consumers would benefit from an interactive, personal training experience at home, iFit’s trainer-led, streaming workouts are now trusted by millions of consumers around the world.

iFit offers workout options for every fitness level and interest—from bodyweight training, boxing, HIIT, yoga, Pilates and more—to connected fitness workouts on NordicTrack home equipment. Patented interactive technology allows iFit Trainers to create workouts for iFit members that automatically adjust the member’s incline, decline, speed and resistance in sync with iFit’s streaming workouts. iFit interactive content is available on NordicTrack, ProForm and Freemotion treadmills, stationary bikes, rowers, ellipticals, strength machines and the iFit app.

ICON Health & Fitness, Inc. is a global health and fitness leader and owner of iFit, NordicTrack, ProForm, Freemotion and other fitness brands. Based in Logan, Utah, the 43-year old company has a multi-decade heritage of innovation and quality. ICON currently holds more than 330 patents, with more than 80 pending, and its products are sold in 116 countries. iFit workouts are streamed in English, Spanish, French and Mandarin Chinese, with more languages planned for 2021.

Join the discussion @iFit , @NordicTrack and @ProForm

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye